Hologic Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: January 29, 2026 results vs estimates
Hologic Inc Forecast
Hologic Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 2.9% a year, a typical one-standard-deviation range is 75.70–76.32 over a week, 75.38–76.64 over a month and 73.82–78.20 over a year. (Signals as of 1 Nov 2026.)
Hologic Inc Price Chart
Hologic Inc Factors
YoY +6.4%
YoY +1.6%
YoY −1.6%
YoY +7.5%
YoY 0.0%
YoY +5.5%
YoY −6.0%
YoY +2.3%
YoY −63.3%
YoY −60.8%
YoY +7.6%
YoY +8.4%
YoY +0.3%
YoY −7.7%
YoY 0.0%
YoY +2.4%
Hologic Inc fundamentals: income statement, balance sheet & cash flow
Hologic Inc reported revenue of $4.10bn and net income of $565.7m in FY2025, the year ended 30 September 2025 — revenue up 1.7% and net income down 28.3% on the prior year. Free cash flow was $920.1m. These figures are as reported in the filings, not restated: 37 fiscal years and 149 quarters of history, back to September 1989. 159 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 30 Sep 2025 | 30 Sep 2024 | 30 Sep 2023 | 30 Sep 2022 | 30 Sep 2021 |
| Revenue | 4,100.5 | 4,030.3 | 4,030.4 | 4,862.8 | 5,632.3 |
| Cost of revenue | 1,599.4 | 1,802.5 | 1,958.9 | 1,865.4 | 1,836.5 |
| Gross profit | 2,501.1 | 2,227.8 | 2,071.5 | 2,997.4 | 3,795.8 |
| Research & development | 248.2 | 272.8 | 294.3 | 283.4 | 276.3 |
| Selling, general & admin. | 1,538.6 | 1,072.4 | 1,108.8 | 1,073.8 | 1,039.2 |
| Operating income | 714.3 | 882.6 | 668.4 | 1,640.2 | 2,480.3 |
| EBITDA | 1,023.7 | 1,296.2 | 1,110.6 | 2,113.4 | 2,861.6 |
| Interest expense | 42.7 | 122.1 | 111.1 | 95.1 | 93.6 |
| Pre-tax income | 681.2 | 865.1 | 676.1 | 1,588.2 | 2,361.1 |
| Income tax | 115.5 | 75.6 | 220.1 | 286.2 | 491.4 |
| Net income | 565.7 | 789.5 | 456.0 | 1,302.0 | 1,871.5 |
Download Hologic Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.HOLX.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Hologic Inc
Explore MacroFinance macro & markets research and analysis.
Hologic Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Hologic Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Hologic Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Hologic Inc (United States)
Hologic Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Hologic Inc?
What is the latest Hologic Inc price?
Is Hologic Inc in an uptrend?
How volatile is Hologic Inc?
What factors affect Hologic Inc?
Which trading strategies trade Hologic Inc?
How are Hologic Inc returns analysed?
Where can I download free Hologic Inc historical data?
Free Hologic Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Hologic Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.HOLX.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-04-07 | 76.01 |
| 2026-04-06 | 76.01 |
| 2026-04-02 | 75.65 |
| 2026-04-01 | 75.6 |
| 2026-03-31 | 75.59 |
| 2026-03-30 | 75.55 |
| 2026-03-27 | 75.67 |
| 2026-03-26 | 75.69 |
| 2026-03-25 | 75.52 |
| 2026-03-24 | 75.55 |
About this stock
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analysis software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology systems; and breast conserving surgery products. In addition, the company provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system. The company sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.